OQRO

Feed News

Explore

Insider trades Fund moves Congressional trades Federal contracts

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

CFO exercised or converted 4,230.53 WST derivative securities | OQRO

Home
Insider trades
West Pharmaceutical Services
CFO exercised or converted 4,230.53 WST derivative securities

Insider trades

Insider trade

CFO exercised or converted 4,230.53 WST derivative securities

Traded Feb 11, 2026 · Filed Feb 13, 2026

West Pharmaceutical ServicesWST

4,230.53
Derivative units

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Feb 11, 2026
Reporting period: Not applicable
Filed with the SEC: Feb 13, 2026

CFOOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0000105770-26-000007

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Filed / recorded

Feb 13, 2026, 2:37 AM UTC

Added to OQRO

Oct 2, 2026, 12:29 PM UTC

Parser

form4-xml-v1

Data quality

Verified: identifiers matched exactly

Issuer

WEST PHARMACEUTICAL SERVICES INC

Issuer CIK

105770

Ticker

WST

Reporting person

Robert W. Mcmahon

Relationship

Officer

Officer title

SVP & Chief Financial Officer

Security

Rst. Stock Unit

Table

Derivative (Table II)

Transaction date

Feb 11, 2026

Transaction code

Shares / units

4,230.525

Price per share

$0.00

Acquired / disposed

Disposed (D)

Shares owned after

8,462.052

Ownership form

Direct

Amendment

Footnotes from the filing

Restricted stock units convert into common stock on a one-for-one basis.
On August 11, 2025, the reporting person was granted 12,670 restricted stock units, vesting in three installments - 4,223 shares (plus dividend equivalents) to vest six months from the grant date, 6,335 shares (plus dividend equivalents) to vest 12 months from the grant date and 2,112 shares (plus dividend equivalents) to vest 24 months from the grant date.